| Business Summary | | Chronimed,
Inc.
is
a
disease-focused
company
specializing
in
specialty
pharmacy
distribution
for
people
with
chronic
health
conditions.
The
Company
distributes
pharmaceuticals
and
provides
specialized
patient
management
services
nationwide
for
people
with
long-term
chronic
conditions
such
as
organ
transplants,
HIV/AIDS,
diabetes,
and
diseases
treated
with
biotech
injectable
medications.
Chronimed
works
directly
with
patients,
providers,
and
payors
to
improve
clinical
and
cost-of-care
outcomes.
On
March
13,
2000,
Chronimed
announced
its
intention
to
spin
off
its
Diagnostic
Products
business
(to
be
named
MEDgenesis
Inc.)
to
shareholders,
contingent
upon
the
satisfaction
of
various
conditions. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Chronimed,
Inc.
is
a
disease-focused
company
specializing
in
specialty
pharmacy
distribution
for
people
with
chronic
health
conditions.
For
the
39
weeks
ended
3/30/01,
revenues
rose
29%
to
$214.4
million.
Net
income
from
continuing
operations
totalled
$2.8
million,
vs.
a
loss
of
$1.7
million.
Revenues
benefited
from
the
acquisition
of
APP
and
new
patients
from
the
Biotech
Injectibles
contract
with
Aetna.
Net
income
reflects
the
absence
of
a
$5.5
million
write-off. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Henry Blissenbach, 58 Chairman,
CEO | $296K | Stephen Ritter, 42 Sr.
VP, Mail-Order | -- | Gregory Keane, 45 VP,
CFO, Treasurer | 230K | Patrick Taffe, 48 VP,
CIO | 241K | Shawn Featherston, 47 VP,
HR | 185K | Dollar
amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|